GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » EV-to-Revenue

Fortress Biotech (FRA:CNB1) EV-to-Revenue : 0.38 (As of May. 13, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Fortress Biotech EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Fortress Biotech's enterprise value is €30.08 Mil. Fortress Biotech's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €78.51 Mil. Therefore, Fortress Biotech's EV-to-Revenue for today is 0.38.

The historical rank and industry rank for Fortress Biotech's EV-to-Revenue or its related term are showing as below:

FRA:CNB1' s EV-to-Revenue Range Over the Past 10 Years
Min: -8.85   Med: 3.3   Max: 245.84
Current: 0.42

During the past 13 years, the highest EV-to-Revenue of Fortress Biotech was 245.84. The lowest was -8.85. And the median was 3.30.

FRA:CNB1's EV-to-Revenue is ranked better than
90.15% of 1036 companies
in the Biotechnology industry
Industry Median: 7.96 vs FRA:CNB1: 0.42

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-13), Fortress Biotech's stock price is €4.131. Fortress Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €10.28. Therefore, Fortress Biotech's PS Ratio for today is 0.40.


Fortress Biotech EV-to-Revenue Historical Data

The historical data trend for Fortress Biotech's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech EV-to-Revenue Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.87 5.55 2.04 0.39 0.33

Fortress Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.92 0.65 0.08 0.33

Competitive Comparison of Fortress Biotech's EV-to-Revenue

For the Biotechnology subindustry, Fortress Biotech's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's EV-to-Revenue falls into.



Fortress Biotech EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Fortress Biotech's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=30.078/78.509
=0.38

Fortress Biotech's current Enterprise Value is €30.08 Mil.
Fortress Biotech's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €78.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fortress Biotech  (FRA:CNB1) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Fortress Biotech's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=4.131/10.275
=0.40

Fortress Biotech's share price for today is €4.131.
Fortress Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €10.28.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fortress Biotech EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (FRA:CNB1) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Fortress Biotech (FRA:CNB1) Headlines

No Headlines